[Nivolumab combined with ipilimumab versus sunitinib monotherapy-SUNNIFORECAST AN 41/16 of the AUO : A phase 2, randomized, open-label study in subjects with previously untreated and advanced (unresectable or metastatic) non-clear cell renal cell carcinoma]

Subjects

Subjects :

Antineoplastic Agents, Immunological
Nivolumab
Treatment Outcome
Antineoplastic Combined Chemotherapy Protocols
Sunitinib
Humans
Antineoplastic Agents
Carcinoma, Renal Cell
Ipilimumab
Kidney Neoplasms

Details

Language :

German

ISSN :

14330563

Volume :

56

Issue :

6

Database :

OpenAIRE

Journal :

Der Urologe. Ausg. A

Accession number :

edsair.pmid..........80fd301b61ddc6df9db13fc0f0d27215